- Home
- LLYVA vs GRFS Comparison
LLYVA vs GRFS Comparison
Compare LLYVA & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LLYVA
- GRFS
- Stock Information
- Founded
- LLYVA 1991
- GRFS 1940
- Country
- LLYVA United States
- GRFS Spain
- Employees
- LLYVA N/A
- GRFS N/A
- Industry
- LLYVA Broadcasting
- GRFS Biotechnology: Pharmaceutical Preparations
- Sector
- LLYVA Industrials
- GRFS Health Care
- Exchange
- LLYVA Nasdaq
- GRFS Nasdaq
- Market Cap
- LLYVA 5.9B
- GRFS 5.5B
- IPO Year
- LLYVA N/A
- GRFS 2006
- Fundamental
- Price
- LLYVA $68.23
- GRFS $7.27
- Analyst Decision
- LLYVA
- GRFS Strong Sell
- Analyst Count
- LLYVA 0
- GRFS 1
- Target Price
- LLYVA N/A
- GRFS N/A
- AVG Volume (30 Days)
- LLYVA 100.8K
- GRFS 704.7K
- Earning Date
- LLYVA 01-01-0001
- GRFS 01-01-0001
- Dividend Yield
- LLYVA N/A
- GRFS N/A
- EPS Growth
- LLYVA N/A
- GRFS N/A
- EPS
- LLYVA N/A
- GRFS 0.27
- Revenue
- LLYVA N/A
- GRFS $7,814,096,584.00
- Revenue This Year
- LLYVA N/A
- GRFS $9.31
- Revenue Next Year
- LLYVA $10.14
- GRFS $7.44
- P/E Ratio
- LLYVA N/A
- GRFS $31.76
- Revenue Growth
- LLYVA N/A
- GRFS 7.21
- 52 Week Low
- LLYVA $32.55
- GRFS $5.30
- 52 Week High
- LLYVA $72.88
- GRFS $9.96
- Technical
- Relative Strength Index (RSI)
- LLYVA 58.59
- GRFS 43.85
- Support Level
- LLYVA $63.91
- GRFS $7.00
- Resistance Level
- LLYVA $65.29
- GRFS $7.53
- Average True Range (ATR)
- LLYVA 1.33
- GRFS 0.24
- MACD
- LLYVA 0.12
- GRFS -0.01
- Stochastic Oscillator
- LLYVA 85.88
- GRFS 27.00
About LLYVA Liberty Media Corporation Series A Liberty Live
Liberty Live Group would be engaged in the operations of Live Nation, and Liberty Media's strategy for that group is to maximize the value of its investment in that company and the other assets attributed to the Liberty Live Group and to use the new Liberty Live common stock to make strategic acquisitions or for other capital raising initiatives.
About GRFS Grifols S.A.
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.